Introduction. The European MDS Study Group reported a deterioration in quality of life in patients with myelodysplastic syndrome (MDS) compared with controls without MDS. In turn,
A narrative review synthesizing evidence from key trials (MAGIC, FLOT4, NeoFLOT, ESOPEC) to evaluate FLOT regimen efficacy in locally advanced gastric and GEJ adenocarcinoma, concluding perioperative chemotherapy remains standard of care but TNT is promising pending long-term survival data.